New oral treatment Erivedge (vismodegib) now authorised for UK use.
Basal Cell Carcinoma (BCC) is the most common form of skin cancer in the UK and is often found on the head and neck. In Gorlin Syndrome individuals can present with multiple BCCs. Erivedge is a major advance for people with advanced BCC (spread to other sites or because of the recurrence after treatment).
Vismodegib, the first of a kind once daily treatment, has been shown to shrink visible lesions (a cancerous change in tissue).
Dr. John Lear, Consultant Dermatologist, Central Manchester University Hospitals said: "Advanced basal cell carcinoma can be socially isolating and highly disfiguring disease that may impair patients' facial structures and senses. Until now, there haven't been any active treatment options available for paitents for who surgery or radiotherapy was not appropriate. Visnmodegib, which has been shown to shrink tumours, is a welcomed new treatment option for patients with advanced BCC and should provide them with a promising new outlook".
For further information see BBC News.
For further information about this treatment view the Patient Information Leaflet
Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello. We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support.
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361